Email updates

Keep up to date with the latest news and content from Alzheimer's Research & Therapy and BioMed Central.

Letter

Plasma tau levels in Alzheimer's disease

Henrik Zetterberg12*, David Wilson3, Ulf Andreasson1, Lennart Minthon4, Kaj Blennow1, Jeffrey Randall3 and Oskar Hansson4

Author Affiliations

1 Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden

2 UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK

3 Quanterix Corporation, 113 Hartwell Avenue, Lexington, MA 02421, USA

4 Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Simrisbanvägen 14, S-212 24 Malmö, Sweden

For all author emails, please log on.

Alzheimer's Research & Therapy 2013, 5:9  doi:10.1186/alzrt163

Published: 28 March 2013

First paragraph (this article has no abstract)

Efforts to find reliable blood biomarkers for Alzheimer's disease (AD) in a highly warranted clinical laboratory test have met with little success. There is no clear change in plasma β-amyloid in AD, and assays for the axonal injury marker tau have been hampered by a lack of analytical sensitivity for accurate measurement in blood samples [1]. Here, the results of a novel ultra-sensitive assay for tau in peripheral blood are reported.